- Home
- REVB vs UOKA Comparison
REVB vs UOKA Comparison
Compare REVB & UOKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- UOKA
- Stock Information
- Founded
- REVB 2020
- UOKA 2002
- Country
- REVB United States
- UOKA United Kingdom
- Employees
- REVB N/A
- UOKA N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- UOKA
- Sector
- REVB Health Care
- UOKA
- Exchange
- REVB Nasdaq
- UOKA NYSE
- Market Cap
- REVB 2.3M
- UOKA 2.6M
- IPO Year
- REVB N/A
- UOKA N/A
- Fundamental
- Price
- REVB $4.31
- UOKA $0.17
- Analyst Decision
- REVB
- UOKA
- Analyst Count
- REVB 0
- UOKA 0
- Target Price
- REVB N/A
- UOKA N/A
- AVG Volume (30 Days)
- REVB 175.9K
- UOKA 27.2M
- Earning Date
- REVB 03-21-2025
- UOKA 03-04-2025
- Dividend Yield
- REVB N/A
- UOKA N/A
- EPS Growth
- REVB N/A
- UOKA N/A
- EPS
- REVB N/A
- UOKA N/A
- Revenue
- REVB N/A
- UOKA $114,849.00
- Revenue This Year
- REVB N/A
- UOKA N/A
- Revenue Next Year
- REVB N/A
- UOKA N/A
- P/E Ratio
- REVB N/A
- UOKA N/A
- Revenue Growth
- REVB N/A
- UOKA 289.97
- 52 Week Low
- REVB $3.34
- UOKA $0.13
- 52 Week High
- REVB $69.44
- UOKA $1.80
- Technical
- Relative Strength Index (RSI)
- REVB 40.86
- UOKA N/A
- Support Level
- REVB $3.80
- UOKA N/A
- Resistance Level
- REVB $4.54
- UOKA N/A
- Average True Range (ATR)
- REVB 0.37
- UOKA 0.00
- MACD
- REVB 0.18
- UOKA 0.00
- Stochastic Oscillator
- REVB 68.13
- UOKA 0.00
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About UOKA MDJM LTD
MDJM Ltd is a real estate service company. The company provides real estate agency services to real estate developer clients, as well as real estate consulting services and independent training services on an as-needed basis. It offers consulting, marketing planning, advertising services, and sales strategies to real estate clients. The company income is derived from commission-based services and minimal consulting and other services. The company has two operating segments; the real estate agent services segment and the hospitality business segment. It derives a majority of its revenue from the People's Republic of China.